Effective for dates of service on or after May 17, 2022, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 Vaccine.

Providers may use administration code 0074A (immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease (COVID-19)] vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose) for billing the booster dose.

More information can be found on the Pfizer-BioNTech COVID-19 Vaccine webpage. Updated provider manual sections will be released in a future Medi-Cal Update.

Effective for dates of service on or after August 1, 2022, targeted Trichomonas vaginalis screening is a benefit under the Family Planning, Access, Care and Treatment (Family PACT) Program.

For additional information, providers can refer to the Benefits: Family Planning section in Part 2 of the manual.

Effective for dates of service on or after July 1, 2022, CPT^® code 90651 (Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonvalent [9vHPV], 2 or 3 dose schedule, for intramuscular use) is a Family Planning, Access, Care and Treatment (Family PACT) Program clinic benefit for females and males 19 to 45 years of age.

Effective for dates of service on or after August 1, 2022, the Family Planning, Access, Care, and Treatment (Family PACT) Program is removing the “reflex from positive” restriction for CPT^® code 86780 (Antibody test; Treponema pallidum [syphilis]) for males and females.

Effective for dates of service on or after January 1, 2022, rates for claims billed with HCPCS code J7304 (contraceptive supply, hormone containing patch, each) and modifier U1 (norelgestromin and ethinyl estradiol transdermal system) or U2 (levonorgestrel and ethinyl estradiol transdermal system) are as follows:

Providers should refer to the Medi-Cal Rates page of the Medi-Cal website for other general rates information.

Note: Rates of services billed with modifiers are not included in the Rates page.

Effective for dates of service on or after August 1, 2022, the dispensing frequency is updated from “one dispensing in 15 days” to “two dispensings in rolling 30 days” for the following drugs reimbursable under S5000 and S5001:

• Cefixime


• Cephalexin


• Ciprofloxacin


• Clindamycin


• Metronidazole


• Sulfamethoxale and Trimethoprim (SMX/TMP)


• Tinidazole

The Medi-Cal Subscription Service (MCSS) is a free service that keeps you up-to-date on the latest Medi-Cal news. Subscribers receive subject-specific emails shortly after urgent announcements and other updates post on the Medi-Cal website.

Subscribing is simple and free!

1. Go to the MCSS Subscriber Form


2. Enter your email address and ZIP code and select a subscriber type


3. Customize your subscription by selecting subject areas for NewsFlash announcements, Medi-Cal Update bulletins and/or System Status Alerts

After submitting the form, a welcome email will be sent to the provided email address. If you are unable to locate the welcome email in your inbox, check your junk email folder.

For more information about MCSS, please visit the MCSS Help page.